Abstract
RWD124 Characteristics of Patients with Advanced Endometrial Cancer Who Received Pembrolizumab As Part of an Early Access Program (EAP) in Accordance with KN-775 Labelling
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have